{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T10:07:16Z","timestamp":1779530836345,"version":"3.53.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40744-026-00851-4","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:24:54Z","timestamp":1776403494000},"page":"545-562","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"13","author":[{"given":"Xingyun","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheyi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"851_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-025-00653-y","volume":"11","author":"I Parodis","year":"2025","unstructured":"Parodis I, Rovin BH, Tektonidou MG, et al. Lupus nephritis. Nat Rev Dis Primers. 2025;11:69.","journal-title":"Nat Rev Dis Primers"},{"key":"851_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.578952","volume":"11","author":"S Hong","year":"2020","unstructured":"Hong S, Healy H, Kassianos AJ. The emerging role of renal tubular epithelial cells in the immunological pathophysiology of lupus nephritis. Front Immunol. 2020;11:578952.","journal-title":"Front Immunol"},{"key":"851_CR3","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1136\/ard-2022-222620","volume":"81","author":"MM Bolognesi","year":"2022","unstructured":"Bolognesi MM, Capitoli G, Galimberti S, et al. Dissecting the histological features of lupus nephritis highlights new common patterns of injury in class III\/IV. Ann Rheum Dis. 2022;81:1704\u201311.","journal-title":"Ann Rheum Dis"},{"key":"851_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40272-023-00609-3","volume":"26","author":"EY Chan","year":"2024","unstructured":"Chan EY, Lai FF, Ma AL, Chan TM. Managing lupus nephritis in children and adolescents. Paediatr Drugs. 2024;26:145\u201361.","journal-title":"Paediatr Drugs"},{"key":"851_CR5","volume":"16","author":"JP Patel","year":"2024","unstructured":"Patel JP, Hardaswani D, Chaniyara SR, et al. Navigating lupus nephritis: a comprehensive review of the current treatment trends. Cureus. 2024;16:e72644.","journal-title":"Cureus"},{"key":"851_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/CM9.0000000000002959","volume":"137","author":"X Jia","year":"2024","unstructured":"Jia X, Lu Y, Zheng X, Tang R, Chen W. Targeted therapies for lupus nephritis: current perspectives and future directions. Chin Med J (Engl). 2024;137:34\u201343.","journal-title":"Chin Med J (Engl)"},{"key":"851_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41584-023-00925-5","volume":"19","author":"CC Mok","year":"2023","unstructured":"Mok CC, Teng YKO, Saxena R, Tanaka Y. Treatment of lupus nephritis: consensus, evidence and perspectives. Nat Rev Rheumatol. 2023;19:227\u201338.","journal-title":"Nat Rev Rheumatol"},{"key":"851_CR8","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1080\/14656566.2024.2416038","volume":"25","author":"G Moroni","year":"2024","unstructured":"Moroni G, Reggiani F, Ponticelli C. Immune-mediating and immunosuppressive pharmacotherapies for proliferative lupus nephritis. Expert Opin Pharmacother. 2024;25:2061\u201376.","journal-title":"Expert Opin Pharmacother"},{"key":"851_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2023.100688","volume":"5","author":"SB Thakare","year":"2023","unstructured":"Thakare SB, So PN, Rodriguez S, Hassanein M, Lerma E, Wiegley N. Novel therapeutics for management of lupus nephritis: what is next? Kidney Med. 2023;5:100688.","journal-title":"Kidney Med"},{"key":"851_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.70021","volume":"28","author":"CC Mok","year":"2025","unstructured":"Mok CC, So H, Hamijoyo L, et al. The 2024 APLAR consensus on the management of lupus nephritis. Int J Rheum Dis. 2025;28:e70021.","journal-title":"Int J Rheum Dis"},{"key":"851_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1525892","volume":"16","author":"DS Chiarenza","year":"2025","unstructured":"Chiarenza DS, Mancini R, Bigatti C, et al. Case report: Single infusion of combined anti-CD20 and anti-CD38 monoclonal antibodies in pediatric refractory lupus nephritis. Front Immunol. 2025;16:1525892.","journal-title":"Front Immunol"},{"key":"851_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83:15\u201329.","journal-title":"Ann Rheum Dis"},{"key":"851_CR13","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1016\/S2665-9913(23)00320-X","volume":"6","author":"EF Chakravarty","year":"2024","unstructured":"Chakravarty EF, Utset T, Kamen DL, et al. Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial. Lancet Rheumatol. 2024;6:e168\u201377.","journal-title":"Lancet Rheumatol"},{"key":"851_CR14","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.2215\/CJN.04830421","volume":"16","author":"G Moroni","year":"2021","unstructured":"Moroni G, Frontini G, Ponticelli C. When and how is it possible to stop therapy in patients with lupus nephritis: a narrative review. Clin J Am Soc Nephrol. 2021;16:1909\u201317.","journal-title":"Clin J Am Soc Nephrol"},{"key":"851_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2024-001319","volume":"11","author":"M Dall'Era","year":"2024","unstructured":"Dall\u2019Era M, Kalunian K, Solomons N, et al. Comparison of a Voclosporin-based triple immunosuppressive therapy to high-dose glucocorticoid-based immunosuppressive therapy: a propensity analysis of the AURA-LV and AURORA 1 studies and ALMS. Lupus Sci Med. 2024;11:e001319.","journal-title":"Lupus Sci Med"},{"key":"851_CR16","first-page":"658","volume":"42","author":"W Nagata","year":"2024","unstructured":"Nagata W, Takayama E, Nakagawa K, et al. Treatment with lysophosphatidic acid improves glomerulonephritis through the suppression of macrophage activation in a murine model of systemic lupus erythematosus. Clin Exp Rheumatol. 2024;42:658\u201365.","journal-title":"Clin Exp Rheumatol"},{"key":"851_CR17","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1001\/jama.2024.2315","volume":"331","author":"CH Siegel","year":"2024","unstructured":"Siegel CH, Sammaritano LR. Systemic lupus erythematosus: a review. JAMA. 2024;331:1480\u201391.","journal-title":"JAMA"},{"key":"851_CR18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/rheumatology\/kead674","volume":"64","author":"Y Chen","year":"2025","unstructured":"Chen Y, Shi N, Lei X, et al. The efficacy of rituximab plus belimumab or telitacicept in refractory lupus nephritis. Rheumatology (Oxford). 2025;64:221\u20137.","journal-title":"Rheumatology (Oxford)"},{"key":"851_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14020584","volume":"14","author":"GM Rossi","year":"2025","unstructured":"Rossi GM, Vaglio A. New treatment regimens, new drugs, and new treatment goals for lupus nephritis. J Clin Med. 2025;14:584.","journal-title":"J Clin Med"},{"key":"851_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1445814","volume":"15","author":"X Liu","year":"2024","unstructured":"Liu X, Chen X, Yang C, Li R, Chen X, Li Q. Biologicals for the treatment of lupus nephritis: a Bayesian network meta-regression analysis. Front Immunol. 2024;15:1445814.","journal-title":"Front Immunol"},{"key":"851_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103418","volume":"23","author":"I Parodis","year":"2024","unstructured":"Parodis I, Depascale R, Doria A, Anders HJ. When should targeted therapies be used in the treatment of Lupus nephritis: early in the disease course or in refractory patients? Autoimmun Rev. 2024;23:103418.","journal-title":"Autoimmun Rev"},{"key":"851_CR22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.0648","volume":"8","author":"Z Dong","year":"2025","unstructured":"Dong Z, Luo P, Sun S, et al. Mizoribine or cyclophosphamide for lupus nephritis: a randomized clinical trial. JAMA Netw Open. 2025;8:e250648.","journal-title":"JAMA Netw Open"},{"key":"851_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25126452","volume":"25","author":"A Miura","year":"2024","unstructured":"Miura A, Narita Y, Sugawara T, Shimizu H, Itoh H. Mizoribine promotes molecular chaperone HSP60\/HSP10 complex formation. Int J Mol Sci. 2024;25:6452.","journal-title":"Int J Mol Sci"},{"key":"851_CR24","volume":"2022","author":"J Chen","year":"2022","unstructured":"Chen J, Liu H, Yin W, Xu Z, Chen Z, Yiu W. The efficacy and safety of Mizoribine versus Mycophenolate Mofetil for the treatment of renal transplantation: a systematic review and meta-analysis. Comput Intell Neurosci. 2022;2022:5717068.","journal-title":"Comput Intell Neurosci"},{"key":"851_CR25","volume":"5","author":"ID Liu","year":"2025","unstructured":"Liu ID, Willis NS, Craig JC, Hodson EM. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database Syst Rev. 2025;5:Cd003594.","journal-title":"Cochrane Database Syst Rev"},{"key":"851_CR26","doi-asserted-by":"publisher","first-page":"5717","DOI":"10.1080\/10408398.2021.1890689","volume":"62","author":"D Ashtary-Larky","year":"2022","unstructured":"Ashtary-Larky D, Bagheri R, Asbaghi O, et al. Effects of resistance training combined with a ketogenic diet on body composition: a systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2022;62:5717\u201332.","journal-title":"Crit Rev Food Sci Nutr"},{"key":"851_CR27","volume":"1","author":"RF Staerkle","year":"2021","unstructured":"Staerkle RF, Vuille-Dit-Bille RN, Soll C, et al. Extended lymph node resection versus standard resection for pancreatic and periampullary adenocarcinoma. Cochrane Database Syst Rev. 2021;1:Cd011490.","journal-title":"Cochrane Database Syst Rev"},{"key":"851_CR28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jclinepi.2021.08.022","volume":"140","author":"E Igelstr\u00f6m","year":"2021","unstructured":"Igelstr\u00f6m E, Campbell M, Craig P, Katikireddi SV. Cochrane\u2019s risk of bias tool for non-randomized studies (ROBINS-I) is frequently misapplied: a methodological systematic review. J Clin Epidemiol. 2021;140:22\u201332.","journal-title":"J Clin Epidemiol"},{"key":"851_CR29","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12916-022-02442-w","volume":"20","author":"C Cui","year":"2022","unstructured":"Cui C, Sun J, McKay KA, Ingre C, Fang F. Medication use and risk of amyotrophic lateral sclerosis-a systematic review. BMC Med. 2022;20:251.","journal-title":"BMC Med"},{"key":"851_CR30","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41391-024-00908-x","volume":"28","author":"F Ditonno","year":"2025","unstructured":"Ditonno F, Pettenuzzo G, Montanaro F, et al. Head-to-head comparison of DaVinci and Hugo\u2122 RAS robotic platforms for robot-assisted radical prostatectomy: a systematic review and meta-analysis of comparative studies. Prostate Cancer Prostatic Dis. 2025;28:309\u201317.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"851_CR31","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.bja.2024.08.030","volume":"133","author":"KC Hung","year":"2024","unstructured":"Hung KC, Chang LC, Ho CN, et al. Efficacy of intravenous iron supplementation in reducing transfusion risk following cardiac surgery: an updated meta-analysis of randomised controlled trials. Br J Anaesth. 2024;133:1137\u201349.","journal-title":"Br J Anaesth"},{"key":"851_CR32","first-page":"795","volume":"5","author":"M Homma","year":"1989","unstructured":"Homma M, Akizuki M, Yokohari R, et al. Clinical evaluation of mizoribine on lupus nephritis: multicenter single-blind comparative study with inactive placebo. Rinsho iyaku (Journal Of Clinical Therapeutics and Medicines). 1989;5:795\u2013824.","journal-title":"Rinsho iyaku (Journal Of Clinical Therapeutics and Medicines)"},{"key":"851_CR33","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00467-009-1341-4","volume":"25","author":"Y Tanaka","year":"2010","unstructured":"Tanaka Y, Yoshikawa N, Hattori S, et al. Combination therapy with steroids and mizoribine in juvenile SLE: a randomized controlled trial. Pediatr Nephrol. 2010;25:877\u201382.","journal-title":"Pediatr Nephrol"},{"key":"851_CR34","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.3760\/cma.j.issn.0366-6999.20140627","volume":"127","author":"XB Feng","year":"2014","unstructured":"Feng XB, Gu F, Chen WW, et al. Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis. Chin Med J. 2014;127:3718\u201323.","journal-title":"Chin Med J"},{"key":"851_CR35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1046\/j.1328-8067.2001.01534.x","volume":"44","author":"Y Aihara","year":"2002","unstructured":"Aihara Y, Miyamae T, Ito SI, et al. Mizoribine as an effective combined maintenance therapy with prednisolone in child-onset systemic lupus erythematosus. Pediatr Int. 2002;44:199\u2013204.","journal-title":"Pediatr Int"},{"key":"851_CR36","doi-asserted-by":"publisher","first-page":"28","DOI":"10.5414\/CNP64028","volume":"64","author":"W Yumura","year":"2005","unstructured":"Yumura W, Suganuma S, Uchida K, et al. Effects of long-term treatment with mizoribine in patients with proliferative lupus nephritis. Clin Nephrol. 2005;64:28\u201334.","journal-title":"Clin Nephrol"},{"key":"851_CR37","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1177\/0961203312458468","volume":"21","author":"A Nomura","year":"2012","unstructured":"Nomura A, Shimizu H, Kishimoto M, et al. Efficacy and safety of multitarget therapy with mizoribine and tacrolimus for systemic lupus erythematosus with or without active nephritis. Lupus. 2012;21:1444\u20139.","journal-title":"Lupus"},{"key":"851_CR38","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1177\/0961203314528553","volume":"23","author":"H Tanaka","year":"2014","unstructured":"Tanaka H, Aizawa T, Watanabe S, Oki E, Tsuruga K, Imaizumi T. Efficacy of mizoribine-tacrolimus-based induction therapy for pediatric lupus nephritis. Lupus. 2014;23:813\u20138.","journal-title":"Lupus"},{"key":"851_CR39","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3109\/s10165-012-0645-6","volume":"23","author":"E Nishi","year":"2013","unstructured":"Nishi E, Kameda H, Ogawa H, et al. Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis. Mod Rheumatol. 2013;23:97\u2013103.","journal-title":"Mod Rheumatol"},{"key":"851_CR40","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s10157-018-1597-8","volume":"22","author":"H Kagawa","year":"2018","unstructured":"Kagawa H, Hiromasa T, Yamanaka R, et al. The first year results of mizoribine\/tacrolimus-based multitarget treatment for consecutive patients with lupus nephritis. Clin Exp Nephrol. 2018;22:1371\u20138.","journal-title":"Clin Exp Nephrol"},{"key":"851_CR41","doi-asserted-by":"publisher","first-page":"417","DOI":"10.5414\/CNP63417","volume":"63","author":"H Tanaka","year":"2005","unstructured":"Tanaka H, Tsugawa K, Nakahata I, Kudo M, Suzuki K, Ito E. Implication of the peak mizoribine for control of serum level of the serum anti-dsDNA antibody titer in patients with lupus nephritis. Clin Nephrol. 2005;63:417\u201322.","journal-title":"Clin Nephrol"},{"key":"851_CR42","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1007\/s00467-006-0120-8","volume":"21","author":"H Tanaka","year":"2006","unstructured":"Tanaka H, Tsugawa K, Suzuki K, Nakahata T, Ito E. Long-term mizoribine intermittent pulse therapy for young patients with flare of lupus nephritis. Pediatr Nephrol. 2006;21:962\u20136.","journal-title":"Pediatr Nephrol"},{"key":"851_CR43","doi-asserted-by":"publisher","DOI":"10.1177\/2050312114533960","volume":"2","author":"N Yagi","year":"2014","unstructured":"Yagi N, Okada K, Sudo Y, Itoh H, Yoshida H, Kuroda T. Long-term post-marketing surveillance of mizoribine for the treatment of lupus nephritis: safety and efficacy during a 3-year follow-up. SAGE Open Med. 2014;2:2050312114533960.","journal-title":"SAGE Open Med"},{"key":"851_CR44","doi-asserted-by":"publisher","first-page":"c165","DOI":"10.1159\/000346149","volume":"121","author":"H Tanaka","year":"2013","unstructured":"Tanaka H, Watanabe S, Aizawa-Yashiro T, et al. Long-term tacrolimus-based immunosuppressive treatment for young patients with lupus nephritis: a prospective study in daily clinical practice. Nephron Clin Pract. 2013;121:c165\u201373.","journal-title":"Nephron Clin Pract"},{"key":"851_CR45","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10067-007-0635-9","volume":"27","author":"H Tanaka","year":"2008","unstructured":"Tanaka H, Tsugawa K, Oki E, Suzuki K, Ito E. Mizoribine intermittent pulse protocol for induction therapy for systemic lupus erythematosus in children: an open-label pilot study with five newly diagnosed patients. Clin Rheumatol. 2008;27:85\u20139.","journal-title":"Clin Rheumatol"},{"key":"851_CR46","doi-asserted-by":"publisher","first-page":"165","DOI":"10.5414\/CNP62165","volume":"62","author":"H Tanaka","year":"2004","unstructured":"Tanaka H, Nakahata T, Tsugawa K, Tsuruga K, Yumura W, Ito E. Mizoribine pulse therapy for patients with flares of lupus nephritis: a 1-year observation. Clin Nephrol. 2004;62:165\u20136.","journal-title":"Clin Nephrol"},{"key":"851_CR47","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3109\/s10165-007-0567-x","volume":"17","author":"T Kuroda","year":"2007","unstructured":"Kuroda T, Hirose S, Tanabe N, et al. Mizoribine therapy for patients with lupus nephritis: the association between peak mizoribine concentration and clinical efficacy. Mod Rheumatol. 2007;17:206\u201312.","journal-title":"Mod Rheumatol"},{"key":"851_CR48","doi-asserted-by":"publisher","first-page":"c73","DOI":"10.1159\/000151721","volume":"110","author":"H Tanaka","year":"2008","unstructured":"Tanaka H, Oki E, Tsuruga K, et al. Mizoribine treatment of young patients with severe lupus nephritis: a clinicopathologic study by the Tohoku Pediatric Study Group. Nephron Clin Pract. 2008;110:c73\u20139.","journal-title":"Nephron Clin Pract"},{"key":"851_CR49","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1007\/s00296-013-2804-2","volume":"33","author":"M Zhang","year":"2013","unstructured":"Zhang M, Xing CY, Liu J. Study of the efficacy of mizoribine in lupus nephritis in Chinese patients. Rheumatol Int. 2013;33:2737\u201342.","journal-title":"Rheumatol Int"},{"key":"851_CR50","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1177\/09612033231193790","volume":"32","author":"S Liu","year":"2023","unstructured":"Liu S, Zhou W. Research progress in functional magnetic resonance imaging assessment of lupus nephritis kidney injury. Lupus. 2023;32:1143\u201354.","journal-title":"Lupus"},{"key":"851_CR51","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/jalm\/jfac036","volume":"7","author":"N Alforaih","year":"2022","unstructured":"Alforaih N, Whittall-Garcia L, Touma Z. A review of lupus nephritis. J Appl Lab Med. 2022;7:1450\u201367.","journal-title":"J Appl Lab Med"},{"key":"851_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.media.2025.103505","volume":"102","author":"X Wang","year":"2025","unstructured":"Wang X, Liu H, Zhang Y, et al. Joint modeling histology and molecular markers for cancer classification. Med Image Anal. 2025;102:103505.","journal-title":"Med Image Anal"},{"key":"851_CR53","doi-asserted-by":"publisher","first-page":"e594","DOI":"10.1016\/S2589-7500(20)30225-9","volume":"2","author":"C Lu","year":"2020","unstructured":"Lu C, Bera K, Wang X, et al. A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study. Lancet Digit Health. 2020;2:e594\u2013606.","journal-title":"Lancet Digit Health"},{"key":"851_CR54","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.34067\/KID.0000000000000531","volume":"5","author":"I Chernova","year":"2024","unstructured":"Chernova I. Lupus nephritis: immune cells and the kidney microenvironment. Kidney360. 2024;5:1394\u2013401.","journal-title":"Kidney360"},{"key":"851_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103211","volume":"21","author":"LE Kwant","year":"2022","unstructured":"Kwant LE, Vegting Y, Tsang ASMWP, et al. Macrophages in lupus nephritis: exploring a potential new therapeutic avenue. Autoimmun Rev. 2022;21:103211.","journal-title":"Autoimmun Rev"},{"key":"851_CR56","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1038\/s41390-023-02747-3","volume":"94","author":"X Zheng","year":"2023","unstructured":"Zheng X, Ouyang X, Cheng C, et al. Efficacy and safety of multi-target therapy in children with lupus nephritis. Pediatr Res. 2023;94:2040\u20136.","journal-title":"Pediatr Res"},{"key":"851_CR57","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.3324\/haematol.2020.278166","volume":"106","author":"RH Larsen","year":"2021","unstructured":"Larsen RH, Utke Rank C, Grell K, et al. Increments in DNA-thioguanine level during thiopurine-enhanced maintenance therapy of acute lymphoblastic leukemia. Haematologica. 2021;106:2824\u201333.","journal-title":"Haematologica"},{"key":"851_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1270443","volume":"14","author":"D Augustin","year":"2023","unstructured":"Augustin D, Lambert B, Robinson M, Wang K, Gavaghan D. Simulating clinical trials for model-informed precision dosing: using warfarin treatment as a use case. Front Pharmacol. 2023;14:1270443.","journal-title":"Front Pharmacol"},{"key":"851_CR59","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2025.2501128","author":"SM Jankovic","year":"2025","unstructured":"Jankovic SM, Mirkovic N, Stojadinovic D, Lukic S. Using validated model informed precision dosing for dose adjustment: superior evidence needed for efficacy and safety. Expert Opin Drug Metab Toxicol. 2025. https:\/\/doi.org\/10.1080\/17425255.2025.2501128.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"851_CR60","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1080\/03007995.2023.2281498","volume":"40","author":"K Hiraga","year":"2024","unstructured":"Hiraga K, Sato I, Kawakami K. Features and prognosis of patients with lupus nephritis receiving glucocorticoid treatment: a descriptive study using a Japanese claims database. Curr Med Res Opin. 2024;40:103\u201311.","journal-title":"Curr Med Res Opin"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00851-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-026-00851-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00851-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T10:01:58Z","timestamp":1779530518000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-026-00851-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["851"],"URL":"https:\/\/doi.org\/10.1007\/s40744-026-00851-4","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Xingyun Wan, Xiaolong Wang, Shuang Liang, Qian Wang, Chao Liu, and Zheyi Dong declare that they have no relevant conflicts of interest to disclose. For full transparency, we disclose that author Zheyi Dong, who co-authored the meta-analysis data source (reference 22), has also previously been an author on publications sponsored by the drug\u2019s manufacturer. The cited work was an academic undertaking, and no commercial entity has influenced the current study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This systematic review and meta-analysis were conducted using data from previously published studies. As no new human participants or animals were involved, and no primary data were collected, separate ethical approval was not required for this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}